Hiroaki Akamatsu

24PUBLICATIONS
188CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Jul 13, 2026
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC.

|Mar 30, 2026
Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Toshiaki Takakura, Ryota Shibaki, Atsushi Washioka

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Jan 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang

Pageof 4

Frequent Collaborators

4 joint publications

Makoto Nishio

4 joint publications

Tetsuya Mitsudomi

4 joint publications

Satoru Miura

3 joint publications

Yasushi Goto